ASSOCIATION OF LOW GFR AND NON-ALCOHOLIC HEPATOSTEATOSIS ON FIBROSCAN OF LIVER

Authors

  • Khurram Baqai
  • Mahvesh Mahmud
  • Maryam Anwar Ziauddin University
  • Shoukat Ali Samejo
  • Nida Hussain
  • Ambreen Wasim

DOI:

https://doi.org/10.55519/JAMC-01-11051

Abstract

Background: Chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD) are becoming a health concern, owing to their increasing incidence and prevalence. Both entities are linked to poor outcomes and increased costs, hence greatly impacting the healthcare system and economy. Therefore, it is imperative to establish the link between the two, so as to prevent disease progression and complications. Methods: The study was an observational retrospective study done in Karachi, from November 2021 to May 2022. It was conducted on 255 patients who were diagnosed with NAFLD, and the presence of CKD was then determined by calculating their GFRs. Results: Out of the 255 patients diagnosed with hepatosteatosis, 76% had a normal GFR, 20% had a mild decrease and 4% were noted to have a moderate reduction in their GFR. When cross-tabulated with CAP score, it was found that 28% had S1 grade steatosis, out of which 85% had a normal GFR, 13% had a mild decrease and 2% had a moderate decrease in GFR. 22% had S2 grade steatosis, out of which 76% had a normal GFR, 18% had a mild decrease and 6% had a moderate reduction in GFR. 50% patients had S3 grade steatosis, out of which 70% had a normal GFR, 25% had a mild decrease and 5% had a moderate reduction in GFR. Conclusion: There is an association present between NAFLD and the development of low GFR. Therefore, it is important that patients diagnosed with NAFLD are regularly screened for CKD, so as to prevent its development and complications.

References

Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020;72(4):785–801.

Wolide AD, Kumela K, Kerga F, Debalke S, Seboka M, Edilu B, et al. Knowledge, attitude, and practices toward chronic kidney disease among care providers in Jimma town: cross-sectional study. BMC Public Health 2020;20(1):1079.

Kim SH, Jo MW, Go DS, Ryu DR, Park J. Economic Burden of Chronic Kidney Disease in Korea Using National Sample Cohort. J Nephrol 2017;30(6):787–93.

Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015;62(1 Suppl):S47–64.

Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease. Clin Liver Dis 2016;20(2):387–401.

Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014;37(6):1729–36.

Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9(10):1370.

Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014;64(4):638–52.

Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism2011;60(5):735–9.

Stringer S, Sharma P, Dutton M, Jesky M, Ng K, Kaur O, Chapple I, et al. The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol 2013;14:95.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604–12.

Asghar MS, Hassan M, Rasheed U, Haider Kazmi SJ, Khan NA, Khalid F, et al. Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease. Cureus 2020;12(10):e11146.

Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, et al. Association between non-alcoholic fatty liver disease and chronic kidney disease: A cross-sectional study. J Clin Med 2020;9(6):1635.

Liu HW, Liu JS, Kuo KL. Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. Ci Ji Yi Xue Zhi 2019;32(1):65–9.

Kasim H, Zatalia SR, Rasyid H, Bakri S, Parewangi ML, Akil F, et al. Correlation Between Non-Alcoholic Fatty Liver and Chronic Kidney Disease. Open Urol Nephrol J 2020;13(1):1–4.

Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, et al. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol 2020;20(1):139.

Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015;127(9-10):355–62.

Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70(2):522–31.

Downloads

Published

2023-01-02